CD8+CD25+调节性T细胞在疾病中的研究进展

doi:10.16352/j.issn.1001-6325.2022.12.1939

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (12): 1939-1944.doi: 10.16352/j.issn.1001-6325.2022.12.1939

CD8⁺CD25⁺调节性T细胞在疾病中的研究进展

文李娜, 陈丽, 段瑞, 李芳^*

山西医科大学第二临床医学院风湿免疫科, 山西太原 030000

收稿日期:2021-07-01 修回日期:2021-12-08 出版日期:2022-12-05 发布日期:2022-11-23
通讯作者: ^* sunshine5670@hotmail.com
基金资助:
山西省留学人员科技活动择优资助项目(晋财社{2018}123号);山西省回国留学人员科研资助项目(2016-117)

Progress of CD8⁺CD25⁺regulatory T cells in diseases

WEN Li-na, CHEN Li, DUAN Rui, LI Fang^*

Department of Rheumatology and Immunology,the Second Hospital of Shanxi Medical University, Taiyuan 030000,China

Received:2021-07-01 Revised:2021-12-08 Online:2022-12-05 Published:2022-11-23
Contact: ^* sunshine5670@hotmail.com

摘要/Abstract

摘要： CD8⁺CD25⁺Treg具有抑制免疫反应和诱导免疫耐受作用。本文综述了CD8⁺CD25⁺Treg在恶性肿瘤、自身免疫性疾病及其他常见病如哮喘、过敏性疾病、2型糖尿病、子痫前期中的变化及相应的作用机制,CD8⁺CD25⁺Treg在不同疾病中的变化不一致,在恶性疾病中升高,而在自身免疫性疾病中降低。进一步加深对CD8⁺CD25⁺Treg的认识将为疾病的防治及预后提供依据。

关键词: CD8⁺CD25⁺Treg, CD8⁺Treg, 调节性T细胞, 自身免疫性疾病, 肿瘤

Abstract: CD8⁺CD25⁺Treg can inhibit immune response and induce immune tolerance. This article reviews the changes and underlying mechanisms of CD8⁺CD25⁺Treg in pathogenesis of malignant tumors, autoimmune diseases and other common diseases such as asthma, allergic diseases, type 2 diabetes, and pre-eclampsia. The changes of CD8⁺CD25⁺Treg in different diseases are inconsistent, cell counting increased in malignant diseases but decreased in autoimmune diseases. Further understanding of CD8⁺CD25⁺Treg would supporte a basis for the prevention, treatment and improving prognosis of these diseases.

Key words: CD8⁺CD25⁺Treg, CD8⁺ Treg, regulatory T cells, autoimmune diseases, tumors

中图分类号:

文李娜, 陈丽, 段瑞, 李芳. CD8⁺CD25⁺调节性T细胞在疾病中的研究进展[J]. 基础医学与临床, 2022, 42(12): 1939-1944.

WEN Li-na, CHEN Li, DUAN Rui, LI Fang. Progress of CD8⁺CD25⁺regulatory T cells in diseases[J]. Basic & Clinical Medicine, 2022, 42(12): 1939-1944.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2022.12.1939

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2022/V42/I12/1939

参考文献

[1]Li A, Herbst RH, Canner D, et al. IL-33 Signaling alters regulatory T Cell diversity in support of tumor development[J]. Cell Rep, 2019, 29: 2998-3008.
[2]Cosmi L, Liotta F, Lazzeri E, et al. Human CD8⁺CD25⁺ thymocytes share phenotypic and functional features with CD4⁺CD25⁺ regulatory thymocytes[J]. Blood, 2003, 102: 4107-4114.
[3]周文超, 蔡祥胜, 熊小敏, 等. CD4~+CD25~+CD127~(Low)调节性T细胞在原发性肝癌患者外周血的表达及临床意义[J]. 国际检验医学杂志, 2020, 41: 403-405+409.
[4]Troncone E, Monteleone G. Smad7 and colorectal carcinogenesis: a double-edged sword[J]. Cancers (Basel), 2019,11:612. doi: 10.3390/cancers11050612.
[5]Olguín JE, Medina-Andrade I, Molina E, et al. Early and partial reduction in CD4(+)Foxp3(+) Regulatory T Cells during colitis-associated colon cancer induces CD4(+) and CD8(+) T Cell activation inhibiting tumorigenesis[J]. J Cancer, 2018, 9: 239-249.
[6]陈书平, 巫艳彬, 吴聪. CD8~+CD25~+FOXP3~+调节性T淋巴细胞在恶性胸腔积液中的表达及其临床意义[J]. 中国癌症防治杂志, 2010, 2: 296-300.
[7]Zahran AM, Nafady-Hego H, Mansor SG, et al. Increa-sed frequency and FOXP3 expression of human CD8(+)CD25(High+) T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma[J]. Hum Immunol, 2019, 80: 510-516.
[8]Zhang S, Wu M, Wang F. Immune regulation by CD8⁺ Treg cells: novel possibilities for anticancer immuno-therapy[J]. Cell Mol Immunol, 2018 Sep;15:805-807.
[9]卢永红.卵巢癌患者组织及外周血CD8~+T细胞中调节性T细胞相关分子标志物的表达及意义[J].实用癌症杂志,2019,34:1271-1274.
[10]Notley CA, Mccann FE, Inglis JJ, et al. ANTI-CD3 therapy expands the numbers of CD4⁺ and CD8⁺ Treg cells and induces sustained amelioration of collagen-induced arthritis[J]. Arthritis Rheum, 2010, 62: 171-178.
[11]Fischer R, Proske M, Duffey M, et al. Selective activa-tion of tumor necrosis factor receptor Ⅱ induces antiinflammatory responses and alleviates experimental arth-ritis[J]. Arthritis Rheumatol, 2018, 70: 722-735.
[12]Tsai YG, Lee CY, Lin TY, et al. CD8⁺ Treg cells associated with decreasing disease activity after intravenous methylprednisolone pulse therapy in lupus nephritis with heavy proteinuria[J]. PLoS One, 2014,9:e81344. doi: 10.1371/journal.pone.0081344.
[13]Mishra S, Liao W, Liu Y, et al. TGF-β and Eomes control the homeostasis of CD8⁺ regulatory T cells[J]. J Exp Med, 2021,218:e20200030. doi: 10.1084/jem.20200030.
[14]买文丽, 韩清娟, 曹文轩, 等. 人源化NOD小鼠中CD8~+CD25~+Tregs的频率和功能研究[J]. 免疫学杂志, 2016, 32: 7-12.
[15]Zhang M, Wang S, Guo B, et al. An altered CD8(+) T cell epitope of insulin prevents type 1 diabetes in humanized NOD mice[J]. Cell Mol Immunol, 2019, 16: 590-601.
[16]Correale J, Villa A. Role of CD8⁺ CD25⁺ FoxP3⁺ regulatory T cells in multiple sclerosis[J]. Ann Neurol, 2010, 67: 625-638.
[17]Eusebio M, Kraszula L, Kupczyk M, et al. Interleukin-2-mediated stat-5 expression levels in CD8⁺CD25⁺ regulatory T cells: the relevance for asthma[J]. J Biol Regul Homeost Agents, 2019,33:1747-1754.
[18]Tsai YG, Yang KD, Wen YS, et al. Allergen-specific immunotherapy enhances CD8⁺CD25⁺CD137+ regulatory T cells and decreases nasal nitric oxide[J]. Pediatr Allergy Immunol,2019,30:531-539.
[19]Lin L, Dai F, Wei J, et al. Influences of CD8⁺ Tregs on peripheral blood mononuclear cells from allergic rhinitis patients[J]. Laryngoscope, 2021,131:E316-E323.
[20]毛亚静, 陆勤, 奚杰, 等. 内皮细胞微粒与CD8~+ CD25~+ FoxP3~+调节T细胞对子痫前期发生发展的作用探究[J]. 中国计划生育和妇产科, 2019, 11: 57-60.
[21]朱静和,蒋凤,刘青员,等.CD8~+CD25~+FoxP3~+调节T细胞在新诊断2型糖尿病患者外周血中的变化及其临床意义[J].中国糖尿病杂志,2020,28:202-206.
[22]Gupta S, Su H, Agrawal S. CD8 Treg cells inhibit B-cell proliferation and immunoglobulin production[J]. Int Arch Allergy Immunol, 2020,181:947-955.
[23]Churlaud G, Pitoiset F, Jebbawi F, et al. Human and mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at steady state and during Interleukin-2 Therapy[J]. Front Immunol, 2015,6:171. doi:10.3389/fimmu.2015.00171.
[24]Van ZL, Arroyo HR, Côrte-Real BF, et al. Fast and efficient genome editing of human FoxP3⁺ Regulatory T Cells[J]. Front Immunol,2021,12:655122.doi: 10.3389/fimmu.2021.655122.

CD8⁺CD25⁺调节性T细胞在疾病中的研究进展

Progress of CD8⁺CD25⁺regulatory T cells in diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王世尊, 张丹, 葛明, 冯海凉, 刘玉琴. 可移植人髓母细胞瘤PUMC-MBT1瘤株的建立与鉴定[J]. 基础医学与临床, 2022, 42(9): 1339-1343.
[2]	李贺同, 任晶晶, 王文豪, 郝敏. 雌激素及其受体协同HPV在宫颈癌肿瘤微环境中作用的研究进展[J]. 基础医学与临床, 2022, 42(9): 1438-1442.
[3]	周美岑, 兰玲, 邓微. RNA结合蛋白在甲状腺癌发病机制中作用的研究进展[J]. 基础医学与临床, 2022, 42(8): 1306-1309.
[4]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[5]	周岚, 张生贵, 胡祖梁, 王添贤, 岳鹏鹏, 于鸿浩. 基于CRISPR/Cas9系统高效编辑小鼠miR let-7a[J]. 基础医学与临床, 2022, 42(6): 857-863.
[6]	马瑞, 杨黎星, 陈秋霞, 仇佳星, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐对小鼠胶质瘤相关巨噬细胞系促癌表型的影响[J]. 基础医学与临床, 2022, 42(5): 701-707.
[7]	李钊璇, 罗云萍, 陈翀. 气液交互法培养小鼠来源的肿瘤类器官的建立及优化[J]. 基础医学与临床, 2022, 42(5): 782-787.
[8]	白小腾, 孙晓红, 赵翔宇, 李子坚. 检测循环细胞游离DNA用于淋巴瘤诊断和评估的研究进展[J]. 基础医学与临床, 2022, 42(4): 661-666.
[9]	覃智慧, 谭德敏, 王旺珍, 张瑶. LRCH1维持狼疮肾炎模型小鼠调节性T细胞的功能[J]. 基础医学与临床, 2022, 42(3): 441-447.
[10]	宋昊昕, 叶菜英, 朱蕾. Blau综合征细胞模型的建立[J]. 基础医学与临床, 2022, 42(3): 406-410.
[11]	刘畅, 郭向阳. 局部麻醉药物在肿瘤转移和复发中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 512-515.
[12]	谢丽君, 朱高红, 赵继华, 张海波, 王娇. 甲状腺癌肿瘤干细胞的来源和存活途径[J]. 基础医学与临床, 2022, 42(2): 321-324.
[13]	曾笛, 张聪敏, 郭金培, 张楠, 马二民. miR-125靶向SMAD4抑制脂多糖诱导的人结肠上皮细胞向肿瘤细胞转化[J]. 基础医学与临床, 2022, 42(2): 249-254.
[14]	尹婕, 潘凌亚, 温仪萍, 黄虹, 曾靖, 李晓莹, 韩甜甜, 金滢, 李艳. 人上皮性卵巢癌细胞系侧群细胞的肿瘤干细胞样细胞生物学特性及膜蛋白差异表达的鉴定[J]. 基础医学与临床, 2022, 42(2): 221-227.
[15]	王玉敏, 陈济超, 王洪权, 王金华, 唐博. MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展[J]. 基础医学与临床, 2022, 42(12): 1930-1934.

CD8+CD25+调节性T细胞在疾病中的研究进展

Progress of CD8+CD25+regulatory T cells in diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

CD8⁺CD25⁺调节性T细胞在疾病中的研究进展

Progress of CD8⁺CD25⁺regulatory T cells in diseases